首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1182366

出血性疾病檢驗的全球市場預測(～2028年):各產品，各類藥物，不同治療，各適應症，各終端用戶，各地區的分析

Bleeding Disorder Testing Market Forecasts to 2028 - Global Analysis By Product, Drug Class, Treatment, Indication, End User and By Geography

出版日期: 2022年12月12日 | 出版商:

Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

全球出血性疾病檢驗的市場規模在2022年達到8,850萬美金，在預測期間內預計將以9.7％的年複合成長率成長，到2028年之前將達到1億5,508萬美元。

本報告提供全球出血性疾病檢驗市場調查，提供市場的推動因素與阻礙因素，市場機會，COVID-19影響，各市場區隔的市場分析，競爭情形，主要企業的簡介等系統性資訊。

北美
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 義大利
- 法國
- 西班牙
- 其他的歐洲
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 紐西蘭
- 韓國
- 其他的亞太地區
南美
- 阿根廷
- 巴西
- 智利
- 其他的南美
中東·非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 卡達
- 南非
- 其他的中東·非洲

第11章主要趨勢

契約，夥伴關係，合作，合資企業
收購與合併
新產品的銷售
擴張
其他的主要策略

第12章企業簡介

Sysmex Corporation
Siemens Healthcare GmbH
Alexion Pharmaceuticals
Abbott
Amgen Inc
F. Hoffmann-La Roche Ltd
Biogen Inc
Alnylam Pharmaceuticals Inc.
Pfizer Inc
HORIBA Ltd
Bayer AG
Xenetic Biosciences Inc
Thermo Fisher Scientific Inc
CSL Behring
Sanofi S.A
Catalyst Biosciences
Grifols, S.A
Octapharma Plasma, Inc
Bristol-Myers Squibb
Johnson & Johnson
Sun Pharma Industries Limited
Kedrion Biopharma Inc
Teva Pharmaceutical Industries Ltd
Takeda Pharmaceutical Company
Dimension Therapeutics Inc
Novo Nordisk A/S
Ferring Pharmaceuticals

簡介目錄圖表

Product Code: SMRC22184

According to Stratistics MRC, the Global Bleeding Disorder Testing Market is accounted for $88.5 million in 2022 and is expected to reach $155.08 million by 2028 growing at a CAGR of 9.7% during the forecast period. Bleeding disorders occur when the body's ability to clot blood is impaired. A clot forms on the infected body part, which is made up of platelets and a specific type of blood cell. This clot prevents germs from entering the blood and also prevents blood from draining from the injured area. Bleeding disorder testing can help determine whether certain clotting factors are involved and measures how long it takes blood to clot. The test evaluates how long it takes the vessels cut to constrict and how long it takes for platelets in the blood to seal off the hole.

According to the National Hemophilia Foundation, Von Willebrand disease is the most common bleeding disorder affecting approximately 1 in every 100 people or up to 1% of the U.S population.

Market Dynamics:

Driver:

The rise in the blood related disorders

Blood related disorders are chronic illness. They are also life threatening as they circulate throughout the blood. Disorders such as liver disorders, anaemia, and other blood coagulation disorders increased and raised the demand for bleeding disorders treatment. These inherited disorders brought lucrative growth in the market.

Restraint:

Scarcity of skilled professionals

The scarcity of skilled professionals and trained expertise will be a major impediment to the growth of the bleeding disorders treatment market. Medication costs will also slow the market's growth rate. Inadequate reimbursement policies will also limit the scope. Unprofessional treatments can cause major impact on the patient's health. This challenge is hindering the growth of the market.

Opportunity:

Government investments for healthcare interoperability

The increase in the funding by the federal government to drive the adoption of these solutions further influences the market. Additionally, the surge in healthcare expenditure, advancements in healthcare infrastructure, and high demand for expanded care delivery positively affect the bleeding disorders treatment market and fueling the market growth.

Threat:

Low adherence to guidelines

The lower focus of the national organizations and other institutions in emerging countries towards increasing the awareness regarding these conditions resulting in the low penetration of testing. This challenge is limiting the early diagnosis and proper care of patients which is hindering the market growth.

COVID-19 Impact

The COVID-19 pandemic has had a major long-term positive impact on the bleeding disorders treatment market. Initially, there was a drop in the market as a result of lockdowns and quarantine measures. However, as the disease spread around the world, the number of laboratories, COVID-19 testing sites, and processing facilities handling SARS-CoV-2 samples, reagents, and vaccines increased exponentially and made the market to sustain.

The product segment is expected to be the largest during the forecast period

The product segment is estimated to have a lucrative growth, due to developing healthcare infrastructure and healthcare access. The rising awareness regarding the disorders are leading to increased demand. Advancements in technology are improving automation and portable analyzers are anticipated to the growth of the market.

The hospital segment is expected to have the highest CAGR during the forecast period

The hospital segment is anticipated to witness the fastest CAGR growth during the forecast period, due to rising technology treatment of the disorders. The hospitals rate is increasing due to the severity of these disorders which is leading to an increased demand of testing instruments and reagents in hospitals and clinics which is propelling the market growth.

Region with highest share:

Europe is projected to hold the largest market share during the forecast period owing to the growing prevalence of disorders in the region. The rising faithfulness to guidelines and the growing patient population increased the demand. The testing instruments and devices are very advanced in this region which propelled the market share.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the growing launch of testing instruments and the escalating number of regulatory approvals. The increasing awareness and diagnosis rate of bleeding disorder has anticipated to fuel the market growth.

Key players in the market

Some of the key players profiled in the Bleeding Disorder Testing Market include Sysmex Corporation, Siemens Healthcare GmbH, Alexion Pharmaceuticals, Abbott, Amgen Inc, F. Hoffmann-La Roche Ltd, Biogen Inc, Alnylam Pharmaceuticals Inc, Pfizer Inc, HORIBA Ltd, Bayer AG, Xenetic Biosciences Inc, Thermo Fisher Scientific Inc, CSL Behring, Sanofi S.A, Catalyst Biosciences, Grifols, S.A, Octapharma Plasma, Inc, Bristol-Myers Squibb, Johnson & Johnson, Sun Pharma Industries Limited, Kedrion Biopharma Inc, Teva Pharmaceutical Industries Ltd, Takeda Pharmaceutical Company, Dimension Therapeutics Inc, Novo Nordisk A/S, Ferring Pharmaceuticals

Key Developments:

In March 2021, F. Hoffmann La Roche Ltd, launched 8 new configurations for Cobas pro integrated solutions with an aim to maximize throughput and increase testing efficiency.

In Feb 2020, Novo Nordisk A/S launched Esperoct, an anti-hemophilic factor, in the United States in February 2020 for the treatment of adults and children with haemophilia A, i.e., to reduce and control bleeding episodes even during surgery.

Products Covered:

Reagents
Consumables
Instruments
Other Products

Drug Classes Covered:

Fibrin Sealants
Desmopressin Acetate
Antifibrinolytics
Plasma Derived Coagulation Factor Concentrates
Recombinant Coagulation Factor Concentrates
Other Drug Classes

Treatments Covered:

Hormone Replacement Therapy
Contraceptives
Clot Stabilizing Drugs
Desmopressin
Fibrin Sealants
Pipeline Analysis
Drugs Applied To Cuts
Other Treatments

Indications Covered:

Von Willebrand Disease
Hemophilia A
Hemophilia B
Other Indications

End Users Covered:

Research Institutes
Hospital
Clinics
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Bleeding Disorder Testing Market, By Product

5.1 Introduction
5.2 Reagents
5.3 Consumables
5.4 Instruments
5.5 Other Products

6 Global Bleeding Disorder Testing Market, By Drug Class

6.1 Introduction
6.2 Fibrin Sealants
6.3 Desmopressin Acetate
6.4 Antifibrinolytics
6.5 Plasma Derived Coagulation Factor Concentrates
6.6 Recombinant Coagulation Factor Concentrates
6.7 Other Drug Classes

7 Global Bleeding Disorder Testing Market, By Treatment

7.1 Introduction
7.2 Hormone Replacement Therapy
7.3 Contraceptives
7.4 Clot Stabilizing Drugs
7.5 Desmopressin
7.6 Fibrin Sealants
7.7 Pipeline Analysis
7.8 Drugs Applied To Cuts
7.9 Other Treatments

8 Global Bleeding Disorder Testing Market, By Indication

8.1 Introduction
8.2 Von Willebrand Disease
8.3 Hemophilia A
8.4 Hemophilia B
8.5 Other Indications

9 Global Bleeding Disorder Testing Market, By End User

9.1 Introduction
9.2 Research Institutes
9.3 Hospital
9.4 Clinics
9.5 Other End Users

10 Global Bleeding Disorder Testing Market, By Geography

10.1 Introduction
10.2 North America
- 10.2.1 US
- 10.2.2 Canada
- 10.2.3 Mexico
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 Italy
- 10.3.4 France
- 10.3.5 Spain
- 10.3.6 Rest of Europe
10.4 Asia Pacific
- 10.4.1 Japan
- 10.4.2 China
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 New Zealand
- 10.4.6 South Korea
- 10.4.7 Rest of Asia Pacific
10.5 South America
- 10.5.1 Argentina
- 10.5.2 Brazil
- 10.5.3 Chile
- 10.5.4 Rest of South America
10.6 Middle East & Africa
- 10.6.1 Saudi Arabia
- 10.6.2 UAE
- 10.6.3 Qatar
- 10.6.4 South Africa
- 10.6.5 Rest of Middle East & Africa

11 Key Developments

11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies

12 Company Profiling

12.1 Sysmex Corporation
12.2 Siemens Healthcare GmbH
12.3 Alexion Pharmaceuticals
12.4 Abbott
12.5 Amgen Inc
12.6 F. Hoffmann-La Roche Ltd
12.7 Biogen Inc
12.8 Alnylam Pharmaceuticals Inc.
12.9 Pfizer Inc
12.10 HORIBA Ltd
12.11 Bayer AG
12.13 Xenetic Biosciences Inc
12.12 Thermo Fisher Scientific Inc
12.14 CSL Behring
12.15 Sanofi S.A
12.16 Catalyst Biosciences
12.17 Grifols, S.A
12.18 Octapharma Plasma, Inc
12.19 Bristol-Myers Squibb
12.2 Johnson & Johnson
12.21 Sun Pharma Industries Limited
12.22 Kedrion Biopharma Inc
12.23 Teva Pharmaceutical Industries Ltd
12.24 Takeda Pharmaceutical Company
12.25 Dimension Therapeutics Inc
12.26 Novo Nordisk A/S
12.27 Ferring Pharmaceuticals

簡介目錄圖表

List of Tables

Table 1 Global Bleeding Disorder Testing Market Outlook, By Region (2020-2028) ($MN)
Table 2 Global Bleeding Disorder Testing Market Outlook, By Product (2020-2028) ($MN)
Table 3 Global Bleeding Disorder Testing Market Outlook, By Reagents (2020-2028) ($MN)
Table 4 Global Bleeding Disorder Testing Market Outlook, By Consumables (2020-2028) ($MN)
Table 5 Global Bleeding Disorder Testing Market Outlook, By Instruments (2020-2028) ($MN)
Table 6 Global Bleeding Disorder Testing Market Outlook, By Other Products (2020-2028) ($MN)
Table 7 Global Bleeding Disorder Testing Market Outlook, By Drug Class (2020-2028) ($MN)
Table 8 Global Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
Table 9 Global Bleeding Disorder Testing Market Outlook, By Desmopressin Acetate (2020-2028) ($MN)
Table 10 Global Bleeding Disorder Testing Market Outlook, By Antifibrinolytics (2020-2028) ($MN)
Table 11 Global Bleeding Disorder Testing Market Outlook, By Plasma Derived Coagulation Factor Concentrates (2020-2028) ($MN)
Table 12 Global Bleeding Disorder Testing Market Outlook, By Recombinant Coagulation Factor Concentrates (2020-2028) ($MN)
Table 13 Global Bleeding Disorder Testing Market Outlook, By Other Drug Classes (2020-2028) ($MN)
Table 14 Global Bleeding Disorder Testing Market Outlook, By Treatment (2020-2028) ($MN)
Table 15 Global Bleeding Disorder Testing Market Outlook, By Hormone Replacement Therapy (2020-2028) ($MN)
Table 16 Global Bleeding Disorder Testing Market Outlook, By Contraceptives (2020-2028) ($MN)
Table 17 Global Bleeding Disorder Testing Market Outlook, By Clot Stabilizing Drugs (2020-2028) ($MN)
Table 18 Global Bleeding Disorder Testing Market Outlook, By Desmopressin (2020-2028) ($MN)
Table 19 Global Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
Table 20 Global Bleeding Disorder Testing Market Outlook, By Pipeline Analysis (2020-2028) ($MN)
Table 21 Global Bleeding Disorder Testing Market Outlook, By Drugs Applied To Cuts (2020-2028) ($MN)
Table 22 Global Bleeding Disorder Testing Market Outlook, By Other Treatments (2020-2028) ($MN)
Table 23 Global Bleeding Disorder Testing Market Outlook, By Indication (2020-2028) ($MN)
Table 24 Global Bleeding Disorder Testing Market Outlook, By Von Willebrand Disease (2020-2028) ($MN)
Table 25 Global Bleeding Disorder Testing Market Outlook, By Hemophilia A (2020-2028) ($MN)
Table 26 Global Bleeding Disorder Testing Market Outlook, By Hemophilia B (2020-2028) ($MN)
Table 27 Global Bleeding Disorder Testing Market Outlook, By Other Indications (2020-2028) ($MN)
Table 28 Global Bleeding Disorder Testing Market Outlook, By End User (2020-2028) ($MN)
Table 29 Global Bleeding Disorder Testing Market Outlook, By Research Institutes (2020-2028) ($MN)
Table 30 Global Bleeding Disorder Testing Market Outlook, By Hospital (2020-2028) ($MN)
Table 31 Global Bleeding Disorder Testing Market Outlook, By Clinics (2020-2028) ($MN)
Table 32 Global Bleeding Disorder Testing Market Outlook, By Other End Users (2020-2028) ($MN)
Table 33 North America Bleeding Disorder Testing Market Outlook, By Country (2020-2028) ($MN)
Table 34 North America Bleeding Disorder Testing Market Outlook, By Product (2020-2028) ($MN)
Table 35 North America Bleeding Disorder Testing Market Outlook, By Reagents (2020-2028) ($MN)
Table 36 North America Bleeding Disorder Testing Market Outlook, By Consumables (2020-2028) ($MN)
Table 37 North America Bleeding Disorder Testing Market Outlook, By Instruments (2020-2028) ($MN)
Table 38 North America Bleeding Disorder Testing Market Outlook, By Other Products (2020-2028) ($MN)
Table 39 North America Bleeding Disorder Testing Market Outlook, By Drug Class (2020-2028) ($MN)
Table 40 North America Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
Table 41 North America Bleeding Disorder Testing Market Outlook, By Desmopressin Acetate (2020-2028) ($MN)
Table 42 North America Bleeding Disorder Testing Market Outlook, By Antifibrinolytics (2020-2028) ($MN)
Table 43 North America Bleeding Disorder Testing Market Outlook, By Plasma Derived Coagulation Factor Concentrates (2020-2028) ($MN)
Table 44 North America Bleeding Disorder Testing Market Outlook, By Recombinant Coagulation Factor Concentrates (2020-2028) ($MN)
Table 45 North America Bleeding Disorder Testing Market Outlook, By Other Drug Classes (2020-2028) ($MN)
Table 46 North America Bleeding Disorder Testing Market Outlook, By Treatment (2020-2028) ($MN)
Table 47 North America Bleeding Disorder Testing Market Outlook, By Hormone Replacement Therapy (2020-2028) ($MN)
Table 48 North America Bleeding Disorder Testing Market Outlook, By Contraceptives (2020-2028) ($MN)
Table 49 North America Bleeding Disorder Testing Market Outlook, By Clot Stabilizing Drugs (2020-2028) ($MN)
Table 50 North America Bleeding Disorder Testing Market Outlook, By Desmopressin (2020-2028) ($MN)
Table 51 North America Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
Table 52 North America Bleeding Disorder Testing Market Outlook, By Pipeline Analysis (2020-2028) ($MN)
Table 53 North America Bleeding Disorder Testing Market Outlook, By Drugs Applied To Cuts (2020-2028) ($MN)
Table 54 North America Bleeding Disorder Testing Market Outlook, By Other Treatments (2020-2028) ($MN)
Table 55 North America Bleeding Disorder Testing Market Outlook, By Indication (2020-2028) ($MN)
Table 56 North America Bleeding Disorder Testing Market Outlook, By Von Willebrand Disease (2020-2028) ($MN)
Table 57 North America Bleeding Disorder Testing Market Outlook, By Hemophilia A (2020-2028) ($MN)
Table 58 North America Bleeding Disorder Testing Market Outlook, By Hemophilia B (2020-2028) ($MN)
Table 59 North America Bleeding Disorder Testing Market Outlook, By Other Indications (2020-2028) ($MN)
Table 60 North America Bleeding Disorder Testing Market Outlook, By End User (2020-2028) ($MN)
Table 61 North America Bleeding Disorder Testing Market Outlook, By Research Institutes (2020-2028) ($MN)
Table 62 North America Bleeding Disorder Testing Market Outlook, By Hospital (2020-2028) ($MN)
Table 63 North America Bleeding Disorder Testing Market Outlook, By Clinics (2020-2028) ($MN)
Table 64 North America Bleeding Disorder Testing Market Outlook, By Other End Users (2020-2028) ($MN)
Table 65 Europe Bleeding Disorder Testing Market Outlook, By Country (2020-2028) ($MN)
Table 66 Europe Bleeding Disorder Testing Market Outlook, By Product (2020-2028) ($MN)
Table 67 Europe Bleeding Disorder Testing Market Outlook, By Reagents (2020-2028) ($MN)
Table 68 Europe Bleeding Disorder Testing Market Outlook, By Consumables (2020-2028) ($MN)
Table 69 Europe Bleeding Disorder Testing Market Outlook, By Instruments (2020-2028) ($MN)
Table 70 Europe Bleeding Disorder Testing Market Outlook, By Other Products (2020-2028) ($MN)
Table 71 Europe Bleeding Disorder Testing Market Outlook, By Drug Class (2020-2028) ($MN)
Table 72 Europe Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
Table 73 Europe Bleeding Disorder Testing Market Outlook, By Desmopressin Acetate (2020-2028) ($MN)
Table 74 Europe Bleeding Disorder Testing Market Outlook, By Antifibrinolytics (2020-2028) ($MN)
Table 75 Europe Bleeding Disorder Testing Market Outlook, By Plasma Derived Coagulation Factor Concentrates (2020-2028) ($MN)
Table 76 Europe Bleeding Disorder Testing Market Outlook, By Recombinant Coagulation Factor Concentrates (2020-2028) ($MN)
Table 77 Europe Bleeding Disorder Testing Market Outlook, By Other Drug Classes (2020-2028) ($MN)
Table 78 Europe Bleeding Disorder Testing Market Outlook, By Treatment (2020-2028) ($MN)
Table 79 Europe Bleeding Disorder Testing Market Outlook, By Hormone Replacement Therapy (2020-2028) ($MN)
Table 80 Europe Bleeding Disorder Testing Market Outlook, By Contraceptives (2020-2028) ($MN)
Table 81 Europe Bleeding Disorder Testing Market Outlook, By Clot Stabilizing Drugs (2020-2028) ($MN)
Table 82 Europe Bleeding Disorder Testing Market Outlook, By Desmopressin (2020-2028) ($MN)
Table 83 Europe Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
Table 84 Europe Bleeding Disorder Testing Market Outlook, By Pipeline Analysis (2020-2028) ($MN)
Table 85 Europe Bleeding Disorder Testing Market Outlook, By Drugs Applied To Cuts (2020-2028) ($MN)
Table 86 Europe Bleeding Disorder Testing Market Outlook, By Other Treatments (2020-2028) ($MN)
Table 87 Europe Bleeding Disorder Testing Market Outlook, By Indication (2020-2028) ($MN)
Table 88 Europe Bleeding Disorder Testing Market Outlook, By Von Willebrand Disease (2020-2028) ($MN)
Table 89 Europe Bleeding Disorder Testing Market Outlook, By Hemophilia A (2020-2028) ($MN)
Table 90 Europe Bleeding Disorder Testing Market Outlook, By Hemophilia B (2020-2028) ($MN)
Table 91 Europe Bleeding Disorder Testing Market Outlook, By Other Indications (2020-2028) ($MN)
Table 92 Europe Bleeding Disorder Testing Market Outlook, By End User (2020-2028) ($MN)
Table 93 Europe Bleeding Disorder Testing Market Outlook, By Research Institutes (2020-2028) ($MN)
Table 94 Europe Bleeding Disorder Testing Market Outlook, By Hospital (2020-2028) ($MN)
Table 95 Europe Bleeding Disorder Testing Market Outlook, By Clinics (2020-2028) ($MN)
Table 96 Europe Bleeding Disorder Testing Market Outlook, By Other End Users (2020-2028) ($MN)
Table 97 Asia Pacific Bleeding Disorder Testing Market Outlook, By Country (2020-2028) ($MN)
Table 98 Asia Pacific Bleeding Disorder Testing Market Outlook, By Product (2020-2028) ($MN)
Table 99 Asia Pacific Bleeding Disorder Testing Market Outlook, By Reagents (2020-2028) ($MN)
Table 100 Asia Pacific Bleeding Disorder Testing Market Outlook, By Consumables (2020-2028) ($MN)
Table 101 Asia Pacific Bleeding Disorder Testing Market Outlook, By Instruments (2020-2028) ($MN)
Table 102 Asia Pacific Bleeding Disorder Testing Market Outlook, By Other Products (2020-2028) ($MN)
Table 103 Asia Pacific Bleeding Disorder Testing Market Outlook, By Drug Class (2020-2028) ($MN)
Table 104 Asia Pacific Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
Table 105 Asia Pacific Bleeding Disorder Testing Market Outlook, By Desmopressin Acetate (2020-2028) ($MN)
Table 106 Asia Pacific Bleeding Disorder Testing Market Outlook, By Antifibrinolytics (2020-2028) ($MN)
Table 107 Asia Pacific Bleeding Disorder Testing Market Outlook, By Plasma Derived Coagulation Factor Concentrates (2020-2028) ($MN)
Table 108 Asia Pacific Bleeding Disorder Testing Market Outlook, By Recombinant Coagulation Factor Concentrates (2020-2028) ($MN)
Table 109 Asia Pacific Bleeding Disorder Testing Market Outlook, By Other Drug Classes (2020-2028) ($MN)
Table 110 Asia Pacific Bleeding Disorder Testing Market Outlook, By Treatment (2020-2028) ($MN)
Table 111 Asia Pacific Bleeding Disorder Testing Market Outlook, By Hormone Replacement Therapy (2020-2028) ($MN)
Table 112 Asia Pacific Bleeding Disorder Testing Market Outlook, By Contraceptives (2020-2028) ($MN)
Table 113 Asia Pacific Bleeding Disorder Testing Market Outlook, By Clot Stabilizing Drugs (2020-2028) ($MN)
Table 114 Asia Pacific Bleeding Disorder Testing Market Outlook, By Desmopressin (2020-2028) ($MN)
Table 115 Asia Pacific Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
Table 116 Asia Pacific Bleeding Disorder Testing Market Outlook, By Pipeline Analysis (2020-2028) ($MN)
Table 117 Asia Pacific Bleeding Disorder Testing Market Outlook, By Drugs Applied To Cuts (2020-2028) ($MN)
Table 118 Asia Pacific Bleeding Disorder Testing Market Outlook, By Other Treatments (2020-2028) ($MN)
Table 119 Asia Pacific Bleeding Disorder Testing Market Outlook, By Indication (2020-2028) ($MN)
Table 120 Asia Pacific Bleeding Disorder Testing Market Outlook, By Von Willebrand Disease (2020-2028) ($MN)
Table 121 Asia Pacific Bleeding Disorder Testing Market Outlook, By Hemophilia A (2020-2028) ($MN)
Table 122 Asia Pacific Bleeding Disorder Testing Market Outlook, By Hemophilia B (2020-2028) ($MN)
Table 123 Asia Pacific Bleeding Disorder Testing Market Outlook, By Other Indications (2020-2028) ($MN)
Table 124 Asia Pacific Bleeding Disorder Testing Market Outlook, By End User (2020-2028) ($MN)
Table 125 Asia Pacific Bleeding Disorder Testing Market Outlook, By Research Institutes (2020-2028) ($MN)
Table 126 Asia Pacific Bleeding Disorder Testing Market Outlook, By Hospital (2020-2028) ($MN)
Table 127 Asia Pacific Bleeding Disorder Testing Market Outlook, By Clinics (2020-2028) ($MN)
Table 128 Asia Pacific Bleeding Disorder Testing Market Outlook, By Other End Users (2020-2028) ($MN)
Table 129 South America Bleeding Disorder Testing Market Outlook, By Country (2020-2028) ($MN)
Table 130 South America Bleeding Disorder Testing Market Outlook, By Product (2020-2028) ($MN)
Table 131 South America Bleeding Disorder Testing Market Outlook, By Reagents (2020-2028) ($MN)
Table 132 South America Bleeding Disorder Testing Market Outlook, By Consumables (2020-2028) ($MN)
Table 133 South America Bleeding Disorder Testing Market Outlook, By Instruments (2020-2028) ($MN)
Table 134 South America Bleeding Disorder Testing Market Outlook, By Other Products (2020-2028) ($MN)
Table 135 South America Bleeding Disorder Testing Market Outlook, By Drug Class (2020-2028) ($MN)
Table 136 South America Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
Table 137 South America Bleeding Disorder Testing Market Outlook, By Desmopressin Acetate (2020-2028) ($MN)
Table 138 South America Bleeding Disorder Testing Market Outlook, By Antifibrinolytics (2020-2028) ($MN)
Table 139 South America Bleeding Disorder Testing Market Outlook, By Plasma Derived Coagulation Factor Concentrates (2020-2028) ($MN)
Table 140 South America Bleeding Disorder Testing Market Outlook, By Recombinant Coagulation Factor Concentrates (2020-2028) ($MN)
Table 141 South America Bleeding Disorder Testing Market Outlook, By Other Drug Classes (2020-2028) ($MN)
Table 142 South America Bleeding Disorder Testing Market Outlook, By Treatment (2020-2028) ($MN)
Table 143 South America Bleeding Disorder Testing Market Outlook, By Hormone Replacement Therapy (2020-2028) ($MN)
Table 144 South America Bleeding Disorder Testing Market Outlook, By Contraceptives (2020-2028) ($MN)
Table 145 South America Bleeding Disorder Testing Market Outlook, By Clot Stabilizing Drugs (2020-2028) ($MN)
Table 146 South America Bleeding Disorder Testing Market Outlook, By Desmopressin (2020-2028) ($MN)
Table 147 South America Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
Table 148 South America Bleeding Disorder Testing Market Outlook, By Pipeline Analysis (2020-2028) ($MN)
Table 149 South America Bleeding Disorder Testing Market Outlook, By Drugs Applied To Cuts (2020-2028) ($MN)
Table 150 South America Bleeding Disorder Testing Market Outlook, By Other Treatments (2020-2028) ($MN)
Table 151 South America Bleeding Disorder Testing Market Outlook, By Indication (2020-2028) ($MN)
Table 152 South America Bleeding Disorder Testing Market Outlook, By Von Willebrand Disease (2020-2028) ($MN)
Table 153 South America Bleeding Disorder Testing Market Outlook, By Hemophilia A (2020-2028) ($MN)
Table 154 South America Bleeding Disorder Testing Market Outlook, By Hemophilia B (2020-2028) ($MN)
Table 155 South America Bleeding Disorder Testing Market Outlook, By Other Indications (2020-2028) ($MN)
Table 156 South America Bleeding Disorder Testing Market Outlook, By End User (2020-2028) ($MN)
Table 157 South America Bleeding Disorder Testing Market Outlook, By Research Institutes (2020-2028) ($MN)
Table 158 South America Bleeding Disorder Testing Market Outlook, By Hospital (2020-2028) ($MN)
Table 159 South America Bleeding Disorder Testing Market Outlook, By Clinics (2020-2028) ($MN)
Table 160 South America Bleeding Disorder Testing Market Outlook, By Other End Users (2020-2028) ($MN)
Table 161 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Country (2020-2028) ($MN)
Table 162 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Product (2020-2028) ($MN)
Table 163 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Reagents (2020-2028) ($MN)
Table 164 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Consumables (2020-2028) ($MN)
Table 165 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Instruments (2020-2028) ($MN)
Table 166 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Other Products (2020-2028) ($MN)
Table 167 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Drug Class (2020-2028) ($MN)
Table 168 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
Table 169 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Desmopressin Acetate (2020-2028) ($MN)
Table 170 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Antifibrinolytics (2020-2028) ($MN)
Table 171 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Plasma Derived Coagulation Factor Concentrates (2020-2028) ($MN)
Table 172 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Recombinant Coagulation Factor Concentrates (2020-2028) ($MN)
Table 173 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Other Drug Classes (2020-2028) ($MN)
Table 174 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Treatment (2020-2028) ($MN)
Table 175 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Hormone Replacement Therapy (2020-2028) ($MN)
Table 176 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Contraceptives (2020-2028) ($MN)
Table 177 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Clot Stabilizing Drugs (2020-2028) ($MN)
Table 178 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Desmopressin (2020-2028) ($MN)
Table 179 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Fibrin Sealants (2020-2028) ($MN)
Table 180 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Pipeline Analysis (2020-2028) ($MN)
Table 181 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Drugs Applied To Cuts (2020-2028) ($MN)
Table 182 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Other Treatments (2020-2028) ($MN)
Table 183 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Indication (2020-2028) ($MN)
Table 184 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Von Willebrand Disease (2020-2028) ($MN)
Table 185 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Hemophilia A (2020-2028) ($MN)
Table 186 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Hemophilia B (2020-2028) ($MN)
Table 187 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Other Indications (2020-2028) ($MN)
Table 188 Middle East & Africa Bleeding Disorder Testing Market Outlook, By End User (2020-2028) ($MN)
Table 189 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Research Institutes (2020-2028) ($MN)
Table 190 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Hospital (2020-2028) ($MN)
Table 191 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Clinics (2020-2028) ($MN)
Table 192 Middle East & Africa Bleeding Disorder Testing Market Outlook, By Other End Users (2020-2028) ($MN)